Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene

Journal of Pathology

Volumn 225, Issue 1, 2011, Pages 63-72

  Koperek, Oskar ^a   Bergner, Oliver ^a   Pichlhöfer, Bettina ^a   Oberndorfer, Felicitas ^a   Hainfellner, Johannes A ^b   Kaserer, Klaus ^c   Horvat, Reinhard ^a   Harris, Adrian L ^d   Niederle, Bruno ^a   Birner, Peter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Labor Kaserer and Salzer OG   (Austria)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CAIX; desmoplasia; HIF 1 ; hypoxia; medullary thyroid carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1; KI 67 ANTIGEN; TENASCIN; UVOMORULIN; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; STAINING; STROMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH;

AGED; CARBONIC ANHYDRASE IV; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FIBROSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; STROMAL CELLS; TENASCIN; THYROID NEOPLASMS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79960899392     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2926     Document Type: Article

References (57)

1. Liotta LA,. Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture. Am J Pathol 1984; 117: 339-348. (Pubitemid 15182474)
2. Kohn EC, Liotta LA,. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55: 1856-1862.
3. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 140: 883-899.
4. Desgrosellier JS, Cheresh DA,. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
5. Dvorak HF,. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659. (Pubitemid 17052899)
6. De Wever O, Mareel M,. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-447. (Pubitemid 36818244)
7. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
8. Zalatnai A,. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr Mol Med 2006; 6: 685-693. (Pubitemid 44377767)
9. Hockel M, Vaupel P,. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276. (Pubitemid 32219813)
10. Sullivan R, Graham CH,. Hypoxia-driven selection of the metastatic phenotype. Cancer Metast Rev 2007; 26: 319-331. (Pubitemid 47101665)
11. Shibaji T, Nagao M, Ikeda N,. Prognostic significance of HIF-1α overexpression in human pancreatic cancer. Anticancer Res 2003; 23: 4721-4727. (Pubitemid 38173890)
12. Kitada T, Seki S, Sakaguchi H,. Clinicopathological significance of hypoxia-inducible factor-1α expression in human pancreatic carcinoma. Histopathology 2003; 43: 550-555. (Pubitemid 38002343)
13. Schindl M, Schoppmann SF, Samonigg H,. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8: 1831-1837. (Pubitemid 34633742)
14. Pugh CW, Gleadle J, Maxwell PH,. Hypoxia and oxidative stress in breast cancer. Hypoxia signalling pathways. Breast Cancer Res 2001; 3: 313-317.
15. Beasley NJ, Wykoff CC, Watson PH,. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 5262-5267. (Pubitemid 32681562)
16. Birner P, Schindl M, Obermair A,. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-4696.
17. Maxwell PH, Dachs GU, Gleadle JM,. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-8109. (Pubitemid 27343784)
18. Forsythe JA, Jiang BH, Iyer NV,. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613. (Pubitemid 26272112)
19. Wang GL, Semenza GL,. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-4308. (Pubitemid 23134215)
20. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-578. (Pubitemid 32250386)
21. Carmeliet P, Dor Y, Herbert JM,. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490. (Pubitemid 28373960)
22. Sly WS, Hu PY,. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995; 64: 375-401.
23. Wykoff CC, Beasley NJ, Watson PH,. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-7083. (Pubitemid 32059187)
24. Rosai J, Carangiu M, DeLellis R,. Atlas of Tumor Pathology: Tumors of the Thyroid Gland. Armed Forces Institute of Pathology: Washington, DC, 1992.
25. Kaserer K, Scheuba C, Neuhold N,. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 2001; 25: 1245-1251. (Pubitemid 32917117)
26. Scheuba C, Kaserer K, Kaczirek K,. Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative 'marker' for lymph node metastases. World J Surg 2006; 30: 853-859. (Pubitemid 43724117)
27. Koperek O, Scheuba C, Cherenko M,. Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. Histopathology 2008; 52: 623-630. (Pubitemid 351442672)
28. Fink M, Weinhusel A, Niederle B,. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. Study Group Multiple Endocrine Neoplasia Austria (SMENA). Int J Cancer 1996; 69: 312-316. (Pubitemid 26298297)
29. Birner P, Preusser M, Gelpi E, Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications. Clin Cancer Res 2004; 10: 6567-6571. (Pubitemid 39346552)
30. Crossey PA, Richards FM, Foster K,. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994; 3: 1303-1308.
31. Kim WY, Kaelin WG,. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004. (Pubitemid 46646218)
32. Baldewijns MM, van Vlodrop IJ, Vermeulen PB,. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221: 125-138.
33. Kondo K, Klco J, Nakamura E,. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1: 237-246. (Pubitemid 41039148)
34. Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004; 10: 6290-6295S.
35. Koch CA, Brouwers FM, Vortmeyer AO,. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer 2006; 6: 131.
36. Erler JT, Bennewith KL, Nicolau M,. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
37. Chiquet-Ehrismann R, Mackie EJ, Pearson CA,. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986; 47: 131-139. (Pubitemid 17181535)
38. Chiquet-Ehrismann R, Tucker RP,. Connective tissues: signalling by tenascins. Int J Biochem Cell Biol 2004; 36: 1085-1089. (Pubitemid 38501560)
39. Sethi T, Rintoul RC, Moore SM,. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662-668. (Pubitemid 29289430)
40. Hauptmann S, Budianto D, Denkert C,. Adhesion and migration of HRT-18 colorectal carcinoma cells on extracellular matrix components typical for the desmoplastic stroma of colorectal adenocarcinomas. Oncology 2003; 65: 174-181. (Pubitemid 37025980)
41. Colpaert C, Vermeulen P, van Beest P,. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001; 39: 416-425. (Pubitemid 32990095)
42. Couvelard A, O'Toole D, Leek R,. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005; 46: 668-676. (Pubitemid 40834826)
43. Colpaert CG, Vermeulen PB, Fox SB,. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 2003; 81: 137-147. (Pubitemid 37211131)
44. Elvidge GP, Glenny L, Appelhoff RJ,. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1α, HIF-2α, and other pathways. J Biol Chem 2006; 281: 15215-15226. (Pubitemid 43855111)
45. Becker A, Hansgen G, Bloching M,. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998; 42: 35-41. (Pubitemid 28435593)
46. Birner P, Jesch B, Friedrich J,. Carbonic anhydrase IX-overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann Surg Oncol 2011; (Epub ahead of print).
47. Van den Eynden GG, Van der Auwera I, Van Laere SJ,. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer 2005; 93: 1128-1136. (Pubitemid 41670697)
48. Vogelstein B, Kinzler KW,. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799. (Pubitemid 39070849)
49. Sherman SI,. Targeted therapy of thyroid cancer. Biochem Pharmacol 80: 592-601.
50. Robinson BG, Paz-Ares L, Krebs A,. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95: 2664-2671.
51. Ravaud A, de la Fouchardiere C, Asselineau J,. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 15: 212-213; author reply, 214.
52. Semenza GL,. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
53. Poon E, Harris AL, Ashcroft M,. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 2009; 11: e26.
54. Guler OO, De Simone G, Supuran CT,. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem 17: 1516-1526.
55. Supuran CT,. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-181. (Pubitemid 351194064)
56. Turcotte S, Chan DA, Sutphin PD,. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008; 14: 90-102. (Pubitemid 351885499)
57. Sutphin PD, Chan DA, Li JM,. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 2007; 67: 5896-5905. (Pubitemid 46985025)